The available evidence indicates that the majority of the curcumin effects are associated with its ability to suppress inflammation [16]. Experimental research during the past few decades has revealed several important pharmacological properties such as anti-inflammatory, anti-oxidant and anti-tumor activities [17]. Clinical trials performed with healthy human subjects as well as cancer patients have all demonstrated low systemic bioavailability of curcumin following oral administration, even at doses of up to 12 g/day [18,19]. However, there was no toxicity observed even at 12g/day dose. Sulforaphane (SFN) has been shown to protect against acetaminophen-induced hepatotoxicity [20], transplacental toxicity [21] and alveolar epithelial cells exposed to cigarette smoke extract [22]. However, there are no systemic sub-acute and sub-chronic toxicity studies reported in
The available evidence indicates that the majority of the curcumin effects are associated with its ability to suppress inflammation [16]. Experimental research during the past few decades has revealed several important pharmacological properties such as anti-inflammatory, anti-oxidant and anti-tumor activities [17]. Clinical trials performed with healthy human subjects as well as cancer patients have all demonstrated low systemic bioavailability of curcumin following oral administration, even at doses of up to 12 g/day [18,19]. However, there was no toxicity observed even at 12g/day dose. Sulforaphane (SFN) has been shown to protect against acetaminophen-induced hepatotoxicity [20], transplacental toxicity [21] and alveolar epithelial cells exposed to cigarette smoke extract [22]. However, there are no systemic sub-acute and sub-chronic toxicity studies reported in